Novartis to expand its human vaccines presence in China through proposed acquisition of a majority stake in Zhejiang Tianyuan
Advertisement
Novartis has reached an agreement to acquire an 85% stake in the Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. as part of a strategic initiative to build a vaccines industry leader in this country and expand the Group's limited presence in this fast-growing market segment. This proposed acquisition will require government and regulatory approvals in China.
Tianyuan is a privately-owned vaccine company offering a range of marketed vaccine products in China and R&D projects focused on various preventable viral and bacterial diseases. Tianyuan has been delivering dynamic and profitable growth, having more than doubled its net sales to approximately USD 25 million in 2008 compared to 2006.
"Novartis has a long-standing commitment to improving healthcare in China. Our future activities with Tianyuan are an important step in our strategy to enhance the prevention of diseases in China with high-quality products," said Dr. Daniel Vasella, Chairman and CEO of Novartis. "The leadership and associates of Tianyuan share with Novartis the same ambition of offering a broad range of vaccines that can prevent many potentially deadly diseases and greatly improve quality of life."
As part of the collaboration, the two companies will work together to expand Tianyuan's product portfolio and R&D pipeline through targeted investments in vaccines innovation, manufacturing technologies and commercial networks. This collaboration is also expected to facilitate the introduction of Novartis vaccines into China, where Novartis currently has a limited presence with an offering of vaccines against influenza and rabies.
Novartis has signed a definitive agreement with the shareholders of Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd., to acquire an 85% stake for approximately RMB 850 million (USD 125 million in cash). The transaction is subject to certain closing conditions, including receipt of government and regulatory approvals in China.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Cytheris announces results of phase IIa study indicating that recombinant interleukin-7 (CYT107) expands CD4 T-Cells in gut mucosa of chronically HIV infected immunological non-responder patients
Chemokine Therapeutics Announces Preliminary Results of CTCE-9908 Phase IB/II Clinical Trial in Late Stage Cancer Patients
Cytheris announces results of phase II study indicating that recombinant Interleukin-7 (CYT107) expands CD4 T-cells in gut mucosa of chronically HIV infected immunological non-responder patients
Horizon Discovery Announces Collaboration with the National Cancer Institute and the National Human Genome Research Institute - Horizon’s rAAV gene targeting to be applied in cancer research programs, enabling the NCI and NHGRI to engineer human isogenic disease models
Antisoma receives FDA approval for oral fludarabine, plans commercialisation deal to bring drug to US patients
